Testosterone Replacement

TRT on the NHS: eligibility, waiting times and what to expect

Clear, practical guidance on how to access and manage testosterone replacement therapy (TRT) via the NHS: eligibility, testing, treatment options, monitoring and risks.

TRT on the NHS – MYTRT resource guide
Medically reviewed by Medical Director · MUDr 2012, Charles University in Prague – First Faculty of Medicine GMC No. 7404207 Last updated: 30 July 2026
Written by GP and Health Data Scientist · MB ChB 2015, University of Liverpool · MSc Health Data Science, University College London GMC No. 7492303

Introduction

Access to Testosterone Replacement Therapy (TRT) on the NHS is a common concern for men with symptoms of low testosterone. In clinic we see patients who are confused about eligibility, testing and what NHS-funded treatment looks like. Patients often ask us whether the NHS will prescribe testosterone, what blood tests are needed, and how long treatment must continue.

The NHS requires both consistent symptoms and biochemical evidence of testosterone deficiency before starting TRT, and most GPs will refer to secondary care when diagnostic uncertainty exists or specialist opinions are needed. In my clinical experience, men with clear clinical signs — reduced libido, persistent fatigue, loss of muscle mass or erectile dysfunction — combined with low morning total testosterone on repeat testing are most likely to be considered for treatment. Treatment choices on the NHS commonly include topical gels and intramuscular testosterone esters, with monitoring for haematocrit, prostate health and cardiovascular risk factors.

Understanding the pathway and the rationale for tests helps set realistic expectations. We explain the need for repeat measurements, assessment of luteinising hormone (LH) to distinguish primary from secondary hypogonadism, and the role of specialist input where fertility preservation or complex comorbidity is a concern. Practical advice on what to bring to appointments — symptom diaries, previous lab results and medication lists — often speeds up assessment and decision-making.

Medical Summary

Clinical consensus for initiating TRT on the NHS requires documented symptoms consistent with androgen deficiency plus reproducible low serum testosterone, measured in the morning on at least two separate occasions. Total testosterone less than about 8 nmol/L is widely accepted as consistent with deficiency; values between 8–12 nmol/L require repeat testing and clinical correlation. Baseline assessment should include LH to differentiate primary from secondary hypogonadism, full blood count, PSA, liver function and cardiovascular risk review. Contraindications include active prostate cancer and uncontrolled polycythaemia; fertility concerns demand specialist discussion. First-line NHS treatments are typically testosterone gels or intramuscular testosterone esters, titrated to restore physiological levels and relieve symptoms. Monitoring schedules usually check testosterone level, haematocrit and PSA at baseline, 3–6 months after initiation and annually thereafter, with more frequent review if abnormalities arise. Referral to secondary care is appropriate for uncertain diagnosis, complex comorbidity or where fertility-sparing options are required, aligning practice with national guidance and specialist society statements.[1][2][3]

References

Understanding Testosterone and TRT on the NHS

Patients often ask us what testosterone actually does and why treatment might be considered on the NHS. Testosterone is the primary male sex hormone produced mainly by the testes. It helps regulate sexual function and libido, supports the development and maintenance of muscle mass and bone density, affects mood and energy levels, and has roles in fat distribution and red blood cell production.

In clinic we see men with a range of symptoms that can be caused by low testosterone (male hypogonadism): reduced sexual desire or erectile problems, persistent fatigue, depressed mood, loss of muscle bulk, and decreased bone strength. The NHS recognises that these symptoms, together with biochemical evidence of low serum testosterone, are the basis for considering testosterone replacement therapy (TRT).[1]

Biochemical diagnosis is not based on a single number alone. Clinicians usually arrange morning blood tests, ideally fasting, and repeat any low result to confirm persistent deficiency. Many UK and international guidelines use thresholds in a range (commonly around 8–12 nmol/L) and emphasise treating the patient, not just the lab value. Clinical judgment is essential, because men with borderline results may or may not be suitable for TRT depending on symptoms and cause.[2]

The aim of TRT on the NHS is to restore testosterone to a symptom-relieving, physiologically appropriate range and to improve quality of life. In practical terms TRT can improve sexual function and libido, increase energy and mood, help regain muscle mass, and protect bone density. In clinic we set clear treatment goals with patients and explain that benefits may take weeks to months, while some effects (for example on libido) can appear sooner.

  • TRT is prescribed when symptoms and confirmed low testosterone suggest clear benefit.
  • Treatment options include injections, transdermal gels or patches; choice depends on clinical factors and patient preference.
  • Monitoring is mandatory: serum testosterone, haematocrit, prostate health and metabolic parameters are checked regularly to balance benefit and risk.

We also discuss causes of low testosterone—some men have primary testicular failure, others have secondary causes such as pituitary disease, obesity, or medication effects—and treat reversible causes where possible. The NHS and specialist guidance recommend careful selection and ongoing review to ensure TRT remains appropriate and safe for each individual.[3]

References

  • NHS — Information on testosterone deficiency and replacement therapy.
  • British Society for Sexual Medicine (BSSM) — Practical guidance on diagnosing and managing testosterone deficiency.
  • Endocrine Society — Clinical practice guidelines on testosterone therapy and monitoring.

NHS Guidelines for Diagnosing Low Testosterone

Patients often ask us how the NHS defines and diagnoses testosterone deficiency (male hypogonadism). In clinic we see that clear criteria help avoid both under‑ and over‑treatment. The NHS and specialist UK guidance from the British Society for Sexual Medicine (BSSM) set out a pragmatic testing pathway based on symptoms plus objective biochemical tests.

The diagnostic process starts with a targeted clinical assessment for typical symptoms (low libido, erectile dysfunction, reduced energy, loss of morning erections, reduced muscle mass). If these symptoms are present, the next step is biochemical testing of serum testosterone. Tests should be taken in the early morning because testosterone has a marked diurnal variation and levels are highest on waking.

The specific blood tests recommended are:

  • Total testosterone (measured in nmol/L), taken as a fasting morning sample on at least two occasions.
  • Sex hormone‑binding globulin (SHBG) to help interpret total testosterone and, when SHBG is abnormal, to calculate or measure free testosterone.
  • Where indicated, measurement of free testosterone (calculated or direct) because total testosterone can be misleading with high or low SHBG.
  • Additional pituitary tests such as luteinising hormone (LH), follicle‑stimulating hormone (FSH) and prolactin to determine primary versus secondary hypogonadism.

The NHS and BSSM both recommend that low testosterone should be confirmed by two separate morning fasting blood tests. In practice we ask patients to have both samples before 11:00 and, where possible, after an overnight fast because acute illness, recent heavy alcohol use and some medications can transiently lower levels. Repeat testing reduces the risk of a false positive result.

Thresholds commonly used in UK practice follow BSSM guidance. A total testosterone below about 8 nmol/L on repeated morning samples is widely accepted as diagnostic of biochemical testosterone deficiency. Levels in the range of 8–12 nmol/L are regarded as borderline; if symptoms consistent with hypogonadism are present, specialist review and consideration of free testosterone measurement or a therapeutic trial may be appropriate. Values consistently above approximately 12 nmol/L generally make hypogonadism unlikely as the cause of symptoms, although individual assessment remains essential.[1]

In clinic we see patients with borderline results who benefit from a structured approach: confirm on two occasions, check SHBG and gonadotrophins, review medications and comorbidities, and discuss risks and benefits of treatment if clinical suspicion remains high. The NICE clinical knowledge summary also supports measurement of testosterone alongside assessment of clinical features and recommends specialist referral when diagnosis is uncertain or when considering testosterone replacement therapy.[2]

These guidelines ensure diagnosis is based on both symptoms and reproducible biochemical evidence. If you or a patient has symptoms suggestive of low testosterone, arrange early‑morning testing and consider repeat measurements before making treatment decisions.

References

Check your T levels

Symptoms of Low Testosterone Recognised by the NHS

In clinic we see a wide range of presentations that prompt GPs to consider low testosterone (male hypogonadism). Patients often ask whether tiredness, low mood or reduced sexual desire could be caused by low testosterone. The NHS highlights that no single symptom is diagnostic, but particular patterns of physical, cognitive and sexual change commonly trigger blood testing and onward referral.[1]

Physical signs and symptoms that lead GPs to investigate include gradual loss of muscle bulk and strength, increased central body fat, and unexplained reductions in bone density or recurrent fractures. Men may also report decreased energy, persistent fatigue and a drop in exercise tolerance. On examination, small or soft testes, reduced body hair and gynaecomastia are important red flags that suggest primary or mixed hypogonadism rather than lifestyle-related causes.

  • Muscle weakness and loss of lean mass
  • Increased abdominal fat and reduced physical stamina
  • Reduced bone density or unexplained fractures
  • Testicular atrophy, loss of body hair, gynaecomastia

Cognitive and psychological changes are commonly reported and often prompt investigation when they are new, persistent, and not fully explained by depression, sleep apnoea, medication or other medical conditions. In clinic we see men describing reduced motivation, poor concentration, slower thinking and low mood. The NHS advises GPs to consider endocrine causes when cognitive symptoms occur with other features of testosterone deficiency rather than in isolation.[1]

  • Low mood, apathy or loss of motivation
  • Impaired concentration and memory complaints
  • Excessive fatigue not explained by sleep or mental health disorders

Sexual symptoms are the most specific triggers for testing in primary care. Men frequently present with reduced libido, fewer spontaneous or morning erections and erectile dysfunction. Fertility concerns, such as reduced sperm count or difficulty conceiving, and sudden loss of sexual function especially with other systemic signs should prompt timely hormonal assessment.

  • Reduced sex drive and loss of spontaneous erections
  • Erectile dysfunction, particularly when associated with low libido
  • Infertility or reduced testicular size

GPs follow NHS pathways and specialist society guidance when deciding to measure testosterone—usually early morning samples and repeat testing if initial values are low—because symptoms overlap with ageing, obesity, depression and chronic disease. The British Society for Sexual Medicine and the Endocrine Society provide further clinical criteria used in secondary care to confirm the diagnosis.[2][3]

References

The Process of Getting TRT on the NHS

Patients often ask us what to expect if they think they need testosterone replacement therapy (TRT) on the NHS. In clinic we see a common pattern: assessment begins in primary care, then moves through diagnostic tests, and—if indicated—referral to secondary care. The pathway is straightforward in principle but can be slow in practice.

The typical step-by-step journey is:

  • Visit your GP for an initial assessment. The GP will take a medical history, review symptoms such as low libido, fatigue or mood change, check medications and look for contributing conditions like diabetes or obesity. A physical examination may be performed.
  • Initial blood tests. GPs usually request morning blood tests to measure total testosterone and may also request LH, FSH, SHBG, full blood count, PSA, liver function and lipids. Low testosterone on at least two separate occasions is usually required before treatment is considered.[1]
  • Referral to a specialist. If results suggest hypogonadism or if the diagnosis is uncertain, the GP will refer you to an endocrinologist, urologist or a sexual dysfunction clinic for further assessment. Specialists may repeat tests, investigate causes and discuss treatment options.
  • Decision and shared care. If a specialist recommends TRT, they will usually initiate treatment and may set up a shared‑care agreement so your GP can continue prescriptions and basic monitoring.

In clinic we see several practical challenges. Waiting times for initial face-to-face appointments with a specialist vary by region and can stretch from a few weeks to several months. Routine, non-urgent referrals commonly wait 3–6 months; in some areas waits of 6–12 months or longer are not unusual, depending on demand and available specialists.[2]

Delays also arise from repeat testing, timing of blood samples (test in the morning), and local policies about prescribing. Some GPs are cautious about long‑term prescribing and require clear specialist guidance or a formal shared‑care arrangement before continuing treatment. Patients often tell us frustration at the number of appointments and the length of time before feeling any benefit.

Practical tips we give patients: book morning blood tests, keep copies of results and clinic letters, and ask your GP about local referral targets. If you have severe symptoms or concerning findings (for example very low testosterone or rapid decline), flag the urgency with your GP so the referral can be prioritised.

References

1. British Society for Sexual Medicine (BSSM) guidance on diagnosis and management of male hypogonadism.

2. NHS information on referrals, waiting times and how local services vary across England, Wales, Scotland and Northern Ireland.

Types of Testosterone Replacement Therapy Available on the NHS

Patients often ask us which testosterone preparations the NHS prescribes. In clinic we see two main routes in routine use: topical gels and intramuscular injections. The choice depends on clinical factors, patient preference and monitoring logistics. National guidance and specialist societies outline how each option is used and monitored.[1][2]

Topical gels (Testogel, Tostran)

Topical testosterone gels commonly prescribed on the NHS include Testogel and Tostran. These are applied daily to clean, dry skin and provide a relatively steady delivery of testosterone with daily dosing. In clinic we see good symptomatic response for many men, particularly those who prefer to avoid injections.

  • Pros: Steadier daily levels; easy self‑administration; greater flexibility to stop quickly if side effects occur.
  • Cons: Risk of transference to partners or children if skin contact occurs; variable absorption between patients; adherence requires daily application and can be affected by bathing or sweating.

Intramuscular injections (Nebido, Sustanon)

The two injectable preparations commonly used on the NHS are Nebido (testosterone undecanoate) and Sustanon (a blend of testosterone esters). Nebido is a long‑acting formulation given every 10–14 weeks in many patients. Sustanon requires more frequent dosing, typically every 2–4 weeks, and can produce more pronounced peaks and troughs.

  • Nebido — Pros: Infrequent injections, improved convenience for many patients, and relatively stable mid‑range testosterone between doses.
  • Nebido — Cons: Larger injection volume, requires clinic or trained self‑injection arrangements, and longer duration to adjust dose if side effects occur.
  • Sustanon — Pros: Familiar preparation, easier to titrate dose because injections are more frequent.
  • Sustanon — Cons: Shorter dosing interval can mean more clinic visits or self‑injections; biochemical and symptomatic fluctuations (mood, energy) between doses are common.

Across all preparations clinicians watch for haemoglobin/haematocrit rises, prostate‑related issues and symptom response, with baseline and periodic checks advised by specialist guidance.[3] In clinic we discuss advantages and potential harms openly: for example, gels suit those who prefer non‑invasive therapy but require advice to avoid transfer, whereas injections suit patients who want less frequent dosing but accept potential fluctuations or injection‑related issues.

Ultimately the NHS offers both pathways and we individualise choice according to clinical response, safety monitoring and patient lifestyle. Shared decision making and regular follow‑up are central to safe, effective testosterone replacement.

References

1. NHS: Testosterone replacement therapy. Available at: https://www.nhs.uk/conditions/male-menopause/

2. British Society for Sexual Medicine: Guidelines on the investigation and management of testosterone deficiency in men. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10307648/

3. Endocrine Society: Testosterone therapy in adult men with hypogonadism — clinical practice guideline. Available at: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/testosterone-treatment-of-men-with-hypogonadism

NHS vs Private TRT: What You Need to Know

Patients often ask us whether to pursue testosterone replacement therapy (TRT) through the NHS or a private clinic. In clinic we see both pathways regularly. Each route has advantages and limitations across waiting times, choice of medication, monitoring frequency and cost. The correct option depends on clinical need, urgency and personal circumstances.

Waiting times are a common deciding factor. On the NHS, referral typically follows assessment by a GP and, when needed, secondary care triage; this can introduce weeks to months of delay depending on local capacity and referral urgency[1]. In private clinics patients usually access specialist review much sooner, often within days to a couple of weeks, because appointments are self-funded and not subject to the same referral bottlenecks.

Choice of medication differs between routes. NHS formularies and local prescribing policies can limit available preparations and brands; clinicians must work within those formularies while aiming for effective treatment. Private clinics often offer a broader range of preparations (injectable testosterone esters, transdermal gels, implants) and specific brands, giving more flexibility to tailor treatment to patient preference and lifestyle.

Monitoring frequency and intensity are critical to safe TRT. In clinic we follow guidance to check baseline testosterone, haematocrit, prostate health (age-appropriate) and lipids, then reassess testosterone and haematocrit shortly after initiation and periodically thereafter. Specialist bodies recommend early review after dose changes and regular follow-up at defined intervals; practice can vary between NHS trusts and private providers but should align with national guidance[2][3].

Cost is straightforward: NHS treatment is free at the point of care for those eligible, though access may be limited by local pathways. Private treatment involves consultation fees, medication costs and ongoing monitoring charges. Some patients choose private care initially for speed and then transfer to NHS follow-up; others remain private for convenience and continuity.

  • Waiting times: NHS slower, private faster.
  • Choice of medication: NHS constrained by formularies; private often offers wider options.
  • Monitoring: Both should follow national guidance; frequency may be greater in private clinics if supported by contract.
  • Cost: NHS free at point of care; private invoiced per service and treatment.

In clinic we advise patients to consider clinical safety first: confirm diagnosis with appropriate blood tests, ensure a clear monitoring plan is in place, and discuss long-term follow-up before starting therapy. If you are weighing NHS against private care, discuss timelines and monitoring responsibilities with your GP or specialist so you can make an informed choice.

References

Monitoring and Follow-up Care on the NHS

Patients often ask us how the NHS checks safety and effectiveness when they start testosterone replacement therapy (TRT). In clinic we see a standard set of blood tests used to monitor treatment response and identify side effects early. The common tests are serum testosterone, full blood count to check haematocrit/haemoglobin, prostate-specific antigen (PSA) in men, and liver function tests (LFTs).

  • Serum testosterone — to confirm levels are back into the target range and to guide dose adjustments.
  • Haematocrit/haemoglobin — TRT can raise red cell mass; a high haematocrit increases clot risk and may require dose change or temporary cessation.
  • PSA — measured at baseline and periodically, because TRT may unmask or accelerate a pre-existing prostate problem.
  • Liver function tests — checked at baseline; significant abnormalities prompt review although serious liver injury from modern TRT is uncommon.

Frequency of monitoring on the NHS follows an initial baseline assessment, then closer checks early on, and annual reviews thereafter. In practice we perform blood tests around three months after starting or changing dose, again at six months if needed, then at least yearly once stable. Haematocrit is commonly checked at three months and annually; if haematocrit rises above accepted thresholds (often cited around 54%) treatment is paused or adjusted and the patient is re-assessed[1][2].

PSA testing is done at baseline and repeated within the first 3–6 months, then annually according to clinical judgement and age-related prostate risk. Liver tests are usually only repeated if abnormalities were present at baseline or if symptoms suggest liver dysfunction. Any abnormal test triggers a clinical review to consider dose reduction, switching formulation, temporary cessation, or referral to secondary care.

We advise patients to keep routine appointments and bring any new symptoms—headaches, visual changes, breathlessness, or breast changes—to clinical attention promptly. Following these monitoring steps on the NHS helps keep TRT effective while managing risks safely[3].

References

References

  1. British Society for Sexual Medicine (BSSM). Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. 2015.
  2. Endocrine Society. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018.
  3. NHS. Testosterone replacement therapy. NHS.UK patient information and guidance.
  4. NICE Clinical Knowledge Summaries (CKS). Testosterone deficiency — male. National Institute for Health and Care Excellence.

Your Questions Answered

Our team has significant expertise and experience in men's health.

Patients usually start by seeing their GP with symptoms suggestive of low testosterone, such as low libido, fatigue and reduced muscle mass. The GP will order morning blood tests to confirm low serum testosterone and may repeat tests to ensure consistent results. If biochemical hypogonadism is confirmed and symptoms are significant, the GP will refer to endocrinology or urology for assessment and treatment planning. For a practical UK-focused guide to pathways and options see TRT UK.[1]

NHS practice follows specialist guidance: treatment is considered for men with consistent biochemical low testosterone plus relevant symptoms of hypogonadism. Tests should be taken in the morning, repeated, and reversible causes (medication, illness, obesity) excluded before starting TRT. Local services may use thresholds and assessment protocols informed by specialist society guidance.[2]

Yes — parenteral testosterone preparations can be prescribed on the NHS when clinically indicated for diagnosed hypogonadism. Choice of formulation and where injections are administered (GP surgery, clinic or self-administered) depends on local formularies and clinical judgement. In clinic we see both long‑acting and short‑acting injectable options used according to patient preference and monitoring needs.[1]

The NHS will not prescribe over‑the‑counter “testosterone boosters” or unlicensed supplements for low testosterone. Only licensed testosterone medicines are prescribed for confirmed hypogonadism after appropriate assessment. Patients often ask us about supplements, but NHS treatment is reserved for proven medical need rather than performance or general enhancement.[1]

Waiting times vary widely by region, service demand and referral urgency, so there is no single national waiting time for TRT assessment. In clinic we see waits ranging from a few weeks up to several months for non‑urgent referrals. The NHS waiting times pages give the most current data for your local area and prioritisation is based on clinical need.[4]

No — the NHS will not prescribe testosterone for bodybuilding, athletic performance or cosmetic enhancement. Treatment is limited to men with diagnosed hypogonadism and appropriate clinical indications. Prescribing for non‑medical use is contrary to clinical guidance and professional standards.[1]

Borderline results usually prompt repeat testing, clinical correlation with symptoms and assessment of other contributing factors such as obesity, sleep apnoea or medications. Some men are managed with observation and lifestyle measures; others may be referred for specialist assessment to consider a monitored trial of therapy. See our practical guidance on testing and interpretation at Testosterone testing on the NHS.[2]

You can request that your GP take over prescribing after private treatment, but the NHS clinician will usually review the diagnosis, current doses and monitoring documentation before accepting shared care. We often advise patients to provide detailed private records to speed the handover and avoid duplication of tests. The NHS team may repeat baseline tests or adjust treatment to meet local prescribing protocols.[1]

Whether TRT is free depends on where you live in the UK and your entitlement to free prescriptions: in England many patients pay per item unless exempt, while Scotland, Wales and Northern Ireland have different arrangements. Hospital‑initiated treatments and clinic-administered services may be provided without additional prescription charges. For costs and funding information see our overview at TRT cost in the UK.[3]

If the NHS declines TRT, alternatives include addressing reversible causes (weight loss, treating sleep apnoea, reviewing medications), ongoing monitoring, or seeking a second opinion from a specialist. Some patients choose private treatment routes but should be aware of monitoring and safety requirements. Specialist societies recommend careful assessment and follow‑up to protect patient safety when considering alternatives.[2]

View All

Related Articles